NASDAQ · LIVN

LivaNova PLC

$80.58 +$2.39 (+3.06%) 1D Pre-market
Charting by TradingView

Key Metrics

$4.30B
Market cap
40.09×
P/E · TTM
$1.43B
Revenue · TTM
$107.15M
Net income
EPS · TTM $1.97
Dividend yield —
Free cash flow $161.04M
Beta · 1Y 1.10
EBITDA · TTM −$197.48M
Gross margin 67.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 6
    The stock moved +15.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.30B
Enterprise value$4.02B
Shares outstanding54.9M
52-wk range$41.02 – $85.27
Avg volume · 20D527.5K
Net cash $272.92M
Book value / share$22.26
IndustryElectromedical & Electrotherapeutic Apparatus
ExchangeNASDAQ
About LivaNova PLC
IPO dateFeb 10, 1993
Employees3300

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E40.09
P/S3.00
P/FCF26.67
EV/EBITDA—
EV/Sales2.81
Graham №$31.40

Profitability

Gross 67.2%
Operating -15.9%
Net 7.5%
FCF 11.2%
ROE / ROIC 8.5% · -21.0%

Financial Health

Current ratio1.33
Quick ratio1.11
Debt / equity0.24
Debt / EBITDA -1.44
Net cash $272.92M
Working capital$251.76M

Cash Flow · TTM

Operating CF $245.59M
Capex −$84.55M
Free cash flow $161.04M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

1.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$31.40 vs $80.58
Trades 2.6× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings